Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 6/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ici-199,441 SCHEMBL7640991 | 1.00 | OPRD1 (1.00) | OPRD1OPRK1OPRM1CYP3A4CYP2D6 | |
| Ici-199,441 SCHEMBL7647023 | 0.99 | OPRD1 (0.98) | OPRD1OPRK1OPRM1CYP3A4CYP2D6 | |
| Ici-199,441 SCHEMBL7062272 | 0.99 | OPRD1 (0.98) | OPRD1OPRK1OPRM1CYP3A4CYP2D6 | |
| SCHEMBL17570398 | 0.99 | OPRD1 (0.98) | OPRD1OPRK1OPRM1CYP3A4CYP2D6 | |
| SCHEMBL17570385 | 0.99 | OPRD1 (0.98) | OPRD1OPRK1OPRM1CYP3A4CYP2D6 | |
| Ici-199,441 SCHEMBL26981188 | 0.98 | OPRD1 (0.96) | OPRD1OPRK1OPRM1CYP3A4CYP2D6 | |
| SCHEMBL21468950 | 0.93 | OPRK1 (0.86) | OPRD1OPRK1OPRM1CYP3A4CYP2D6 | |
| SCHEMBL21120210 | 0.91 | OPRK1 (0.83) | OPRD1OPRK1OPRM1CYP3A4CYP2D6 | |
| SCHEMBL9457102 | 0.90 | OPRD1 (0.81) | OPRD1OPRK1OPRM1CYP3A4CYP2D6 | |
| SCHEMBL9457235 | 0.90 | OPRD1 (0.81) | OPRD1OPRK1OPRM1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0254545-B1 | DIAMINE COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-06 | — | — | EP | claimed |
| EP-0254545-A2 | Diamine compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-01-27 | — | — | EP | claimed |
| US-20240180895-A1 | USE OF KAPPA OPIOID RECEPTOR AGONISTS TO TREAT CARDIOVASCULAR DISEASE | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2024-06-06 | — | — | US | disclosed |
| EP-4302779-A1 | CANCER THERAPEUTIC AGENT | Socium Inc. (JP) | 2024-01-10 | — | — | EP | disclosed |
| CN-116615242-A | Cancer therapeutic agent | 寿协株式会社 | 2023-08-18 | — | — | CN | disclosed |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | disclosed |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | ACER THERAPEUTICS INC. | 2021-02-04 | — | — | US | disclosed |
| EP-3013812-B1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-08-22 | — | — | US | disclosed |
| EP-3237388-B1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | NEKTAR THERAPEUTICS (US) | 2019-07-03 | — | — | EP | disclosed |
| US-8338442-B2 | Opioid receptors antagonist ; restless leg syndrome; sleep disorders | TORAY INDUSTRIES, INC. (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | KOESTER HUBERT | 2011-05-19 | — | — | US | disclosed |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100248264-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20040116456-A1 | Remedies for psychoneurosis | TORAY INDUSTRIES, INC. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1380306-A1 | REMEDIES FOR PSYCHONEUROSIS | TORAY INDUSTRIES, INC. (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-5804595-A | ANTIINFLAMMATORY AGENT TO TREAT PAIN CAUSED BY RHEUMATOID ARTHRITIS AND LAPAROSCOPIC SURGERY | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1998-09-08 | — | — | US | disclosed |
| EP-0254545-B1 | DIAMINE COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-06 | — | — | EP | disclosed |
| EP-0254545-A2 | Diamine compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRD1 1577/4885OPRK1 554/4885OPRM1 814/4885 |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRD1 1577/4885OPRK1 554/4885OPRM1 814/4885 |
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PTMS, QPCTL, SRMS | OPRD1 4447/4885OPRK1 4226/4885OPRM1 4273/4885 |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | VASP, PDE3A, PDE2A | OPRD1 1577/4885OPRK1 554/4885OPRM1 814/4885 |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRD1 1577/4885OPRK1 554/4885OPRM1 814/4885 |
| US-20240180895-A1 | USE OF KAPPA OPIOID RECEPTOR AGONISTS TO TREAT CARDIOVASCULAR DISEASE | OPRK1, OPRL1, OPRM1 | OPRD1 4/4885OPRK1 1/4885OPRM1 3/4885 |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CHLSN, PTMS, SRMS | OPRD1 4811/4885OPRK1 4581/4885OPRM1 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.